BNR Stock Analysis: Brenntag SE | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 8.114m EUR | 12M Return: 2.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.0M
EPS Trend: -83.7%
Qual. Beats: 0
Rev. Trend: -91.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Brenntag SE is a German-headquartered global distributor of chemicals and ingredients, operating across Europe, North America, and Asia. Founded in 1874 and based in Essen, the company runs two segments: Brenntag Essentials and Brenntag Specialties, serving end markets such as nutrition, pharma, beauty and personal care, water treatment, coatings, adhesives, polymers, and construction.
Beyond straightforward chemical distribution, Brenntag adds value through services including just-in-time delivery, product mixing and blending, repackaging, inventory management, drum return handling, technical and formulation support, regulatory expertise, and digital sales channels. This service-oriented positioning is typical of specialty chemical distributors, which generate a significant portion of revenue from value-added services such as formulation support and supply chain management rather than from chemical manufacturing itself.
- Brenntag Specialties margin expansion outpaces lower-margin Essentials segment
- Industrial destocking pressures Essentials volumes and pricing in Europe and Americas
- Capital allocation prioritizes debt reduction and targeted M&A in higher-growth verticals
| Net Income: 228.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.95 > 1.0 |
| NWC/Revenue: 14.21% < 20% (prev 10.47%; Δ 3.74% < -1%) |
| CFO/TA 0.08 > 3% & CFO 947.4m > Net Income 228.2m |
| Net Debt (3.26b) to EBITDA (1.16b): 2.80 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.4m) vs 12m ago -0.09% < -2% |
| Gross Margin: 18.55% > 18% (prev 22.08%; Δ -3.53% > 0.5%) |
| Asset Turnover: 129.2% > 50% (prev 140.1%; Δ -10.83% > 0%) |
| Interest Coverage Ratio: 3.77 > 6 (EBIT TTM 578.2m / Interest Expense TTM 153.3m) |
| A: 0.19 (Total Current Assets 4.93b - Total Current Liabilities 2.83b) / Total Assets 11.2b |
| B: 0.33 (Retained Earnings 3.75b / Total Assets 11.2b) |
| C: 0.05 (EBIT TTM 578.2m / Avg Total Assets 11.4b) |
| D: 0.67 (Book Value of Equity 4.48b / Total Liabilities 6.68b) |
| Altman-Z'' = 3.36 = A |
| DSRI: 1.17 (Receivables 2.83b/2.67b, Revenue 14.8b/16.3b) |
| GMI: 1.19 (GM 22.08% / 18.55%) |
| AQI: 1.01 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.91 (Revenue 14.8b / 16.3b) |
| TATA: -0.06 (NI 228.2m - CFO 947.4m) / TA 11.2b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at EUR 56.08 with a total of 244,193 shares traded. Over the past week, the price has changed by +4.98%, over one month by +2.26%, over three months by +0.72% and over the past year by +2.68%.
Current recommended Stop Loss: 54.30 (which is 3.2% or 1.3 ATR below the current price).
Brenntag SE has no consensus analysts rating.
P/E Trailing = 35.5696
P/E Forward = 10.8578
P/S = 0.5497
P/B = 1.7209
P/EG = 1.138
Revenue TTM = 14.8b EUR
EBIT TTM = 578.2m EUR
EBITDA TTM = 1.16b EUR
Long Term Debt = 2.60b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 413.0m EUR (from shortTermDebt, last quarter)
Debt = 3.95b EUR (from shortLongTermDebtTotal, last quarter) + Leases 571.0m
Net Debt = 3.26b EUR (calculated: Debt 3.95b - CCE 696.0m)
Enterprise Value = 11.4b EUR (8.11b + Debt 3.95b - CCE 696.0m)
Interest Coverage Ratio = 3.77 (Ebit TTM 578.2m / Interest Expense TTM 153.3m)
EV/FCF = 17.34x (Enterprise Value 11.4b / FCF TTM 655.7m)
FCF Yield = 5.77% (FCF TTM 655.7m / Enterprise Value 11.4b)
FCF Margin = 4.44% (FCF TTM 655.7m / Revenue TTM 14.8b)
Net Margin = 1.55% (Net Income TTM 228.2m / Revenue TTM 14.8b)
Gross Margin = 18.55% ((Revenue TTM 14.8b - Cost of Revenue TTM 12.0b) / Revenue TTM)
Gross Margin QoQ = 12.89% (prev 9.82%)
Tobins Q-Ratio = 1.02 (Enterprise Value 11.4b / Total Assets 11.2b)
Interest Expense / Debt = 3.88% (Interest Expense 153.3m / Debt 3.95b)
Taxrate = 47.01% (206.7m / 439.7m)
NOPAT = 306.4m (EBIT 578.2m * (1 - 47.01%))
Current Ratio = 1.74 (Total Current Assets 4.93b / Total Current Liabilities 2.83b)
Debt / Equity = 0.88 (Debt 3.95b / totalStockholderEquity, last quarter 4.48b)
Debt / EBITDA = 2.80 (Net Debt 3.26b / EBITDA 1.16b)
Debt / FCF = 4.97 (Net Debt 3.26b / FCF TTM 655.7m)
Total Stockholder Equity = 4.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 228.2m / Total Assets 11.2b)
RoE = 5.27% (Net Income TTM 228.2m / Total Stockholder Equity 4.33b)
RoCE = 8.34% (EBIT 578.2m / Capital Employed (Equity 4.33b + L.T.Debt 2.60b))
RoIC = 3.79% (NOPAT 306.4m / Invested Capital 8.09b)
WACC = 4.84% (E(8.11b)/V(12.1b) * Re(6.20%) + D(3.95b)/V(12.1b) * Rd(3.88%) * (1-Tc(0.47)))
Discount Rate = 6.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -9.67 | Cagr: -0.44%
[DCF] Terminal Value 77.96% ; FCFF base≈621.6m ; Y1≈712.3m ; Y5≈1.05b
[DCF] Fair Price = 86.60 (EV 15.8b - Net Debt 3.26b = Equity 12.5b / Shares 144.4m; r=8.35% [WACC [floored]]; 5y FCF grow 14.95% → 2.50% )
EPS Correlation: -83.72 | EPS CAGR: -26.88% | SUE: -0.38 | # QB: 0
Revenue Correlation: -91.47 | Revenue CAGR: -6.05% | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.03 | Chg30d=-3.10% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.04 | Chg30d=-9.60% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=3.87 | Chg30d=+3.71% | Revisions=+62% | GrowthEPS=+72.8% | GrowthRev=+0.7%
EPS next Year (2027-12-31): EPS=4.17 | Chg30d=-1.42% | Revisions=+67% | GrowthEPS=+7.7% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: +56% (up=11, down=2)